Ester-oil composition 'bioprotection' for treating asthenic syndrome in patients with dyscirculatory encephalopathy
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the pharmaceutical industry, particularly to a composition for treating asthenic syndrome in patients with dyscirculatory encephalopathy. An ester-oil composition for treating asthenic syndrome in the patients with dyscirculatory encephalopathy contains eucalyptus, mint, pine, cedar, lavender, carnation, flax essences taken in certain relations.
EFFECT: composition is effective for treating asthenic syndrome in the patients with dyscirculatory encephalopathy; it causes the selective harmonising action on the central nervous system, regulates the emotional status, improves cognitive functions, reduces clinical manifestations of asthenic syndrome considerably and improves the quality of life in the patients with dyscirculatory encephalopathy.
1 tbl, 1 ex
The invention relates to medicine, specifically to the creation of herbal medicines for the treatment of dyscirculatory encephalopathy (DE).
The problem of chronic progressive vascular diseases of the brain being nominated by one of the leading places in modern cardiology. In recent years, an increasing number of patients with vascular diseases of the brain. DAE attributed to free radical pathology that brings to the fore in the pathogenesis of the disease processes of lipid peroxidation. The system of protection against the damaging effects of reactive oxygen species and products of their interaction with the main substrates of peroxidation of polyunsaturated fatty acids involves a number of enzyme systems (superoxide dismutase, catalase, glutathione peroxidase, etc.), localized in places of accumulation of active intermediates. In addition, the hydrophilic and hydrophobic phases of the cell present-enzymatic antioxidants, including ascorbate, a-tocopherol, glutathione, carotenoids, flavonoids and polyphenolic compounds nature occupy a leading place (Pospelov, M. L. the Use of medicinal properties of spices in the traditional systems of medicines / O. D. of Barnaul, M. L. Pospelova, M. A. Zaitseva // Integrative medicine 2010: proceedings of the international. forum. - M., 2010. - P. 159-160; Pospelova,M. L. The level of markers of endothelial dysfunction in patients with different severity of atherosclerosis brachiocephalic arteries / M. L. Pospelova, O. D. Barnaul, O. Y. Matvienko et al. // Man and Medicine: proceedings of the XVII Grew. NAT. congruence. - M., 2010. - S. 223-224; Pospelova, M. L. Markers of inflammation in atherosclerosis, the activity of the fibrinolysis system in patients with symptomatic and asymptomatic atherosclerosis brachiocephalic arteries / M. L. Pospelova, O. D. Barnaul, T. V. Osipova // Systemic circulation, hemorheology and microcirculation: proceedings of the VIII Intern. Conf. - Yaroslavl, 2011. - P. 73). Great place in the clinical picture DAE is a emotional personality disorders. In the initial stages of the disease they are presented asthenic symptom complex with a predominantly hypersthenic manifestations, irritability, loss of sleep, confusion, reduced alertness, headache, sensation of noise in the head. Modern methods of treatment of DE with the help of drugs do not solve the problem of asthenic disorders. Prolonged use of pharmacological agents reduces their effectiveness, contributes to the development of complications and the appointment of new medicines. The first in the world practice of medicine for the treatment of asthenia steel adaptogens, the mechanism of which is realized through the increased synthesis of DOPA�ina, such as ginseng, Manchurian aralia, Golden root (Rhodiola rosea), Rhaponticum carthamoides (maral root), schisandra chinensis, sterculia platanoides, Eleutherococcus senticosus, zamanihi high, pantokrina (St George's V. P. Komissarenko, N. F., Dmitruk, S. E. Biologically active substances of medicinal plants. - Novosibirsk: Nauka. - 333 p.; Clinical pharmacology. V. G. Kukes. - Moscow. Moscow: GEOTAR - medicine. - 1999. - 526 p.).
As an independent method or in combination with other types of physiotherapy and medicines used hydrocromotherapy. It is reasonable to prescribe oxygen therapy in the form of oxygen cocktails that has a General stimulating effect and improves the condition of the nervous system. The combination of aeroionotherapy and oxygen therapy gives good clinical effect: improves health, memory, headaches disappear, reduced vestibular and emotional-volitional disorders. The known method coaching therapy intermittent hypoxic exposure by inhalation of air-nitrogen mixture containing 10% oxygen (Neretin, V. J. Complex therapy of chronic ischemia of the brain. - M., 2002). New in the treatment of DAE procedures have become combined effects of light, aromatic oils, heat, massage, music and aeroionotherapy air. (Rybkin V. M., Bragar A. S., MA�fishing I. N., Smolsky O. E. Comprehensive rehabilitation of patients with discirculatory encephalopathy / Rehabilitation and physiotherapy. 2008. - No. 6). In the literature, there are evidence of the successful use of acupuncture and herbal medicine (Morozov O. G., Zdebski V. I., A. A. Yaroshevsky Rehabilitation treatment of chronic cerebral ischemia with the use of methods of acupuncture and Eastern herbal medicine // international journal of neurological, 2010. - 8(38)). Leaf extract gingko biloba has a nonspecific anti-hypoxic effect on the tissue of the entire body, including at the level of neurons. Affects neuroransmitters transsynaptically transmission, affects the release, re-uptake and breakdown of neurotransmitters (norepinephrine, dopamine, acetylcholine) and their ability to connect with membrane receptors. Contained in preparations of flavonoids bind free radicals and neutralize their damaging effects (Gromova O. A., Burtsev E. M., Limanowa O. A. structural Features of the spectrum of a standardized extract of Ginkgo biloba on the example of bilobil and its antioxidant activity // Free radicals and human disease. - Smolensk, 1999. - P. 52-56; Chandrasekaran K, Mehrabian z, Spinnewyn B. Neuroprotective effects of bilobalide, a component of Ginkgo biloba extract (EGb 761) in global brain ischemia and in excitotoxicity-induced neuronal death // Pharmacopsychiatry. - 2003. - Vol.36, No. 1. - P. 89-94.Inhaling the stimulating fragrance of peppermint rosemary, Basil has resulted not only in a clinically significant improvement in mental alertness, more clearly manifested in the performance of intellectual tasks, but was accompanied by an increase in the number of beta waves in contrast to the control group, where the specified was not observed. Inhalation of soothing aromas of Valerian, lavender, on the contrary, there was an increase in the number of alpha, theta and Delta waves. The positive influence of biologically active substances of plants on cerebral circulation is proved by researches of L. S. Leszczynski with co-authors (Soldatchenko S. S., G. F. Kashchenko Prevention and treatment of diseases of the essential oils. - Stavropol, 1998. - 144 p.). L. G. Dudchenko reports on the effective use of aromatherapy in patients with hypertension, when along with the hypotensive activity of the essential oil has beneficial effects on clinical indicators: headache, tinnitus, dizziness. (Dudchenko L. G Fragrances health (treatment of aromatic plants and essential oils) / ed. by K. V. Krivenko. - Kiev: Globe, 1997. - 150 p.) have also been found to effectively carry out aromatherapy can not only in the period of wakefulness of a person, but during sleep, which is confirmed by the distinct electroencephalographic changes, the dynamics of the cardiac frequency R�TMA, blood pressure, electrocardiographic indicators. Clinically proven that even the inhalation of the aroma of apples is able to reduce the pathogenic effects of stress, normalize blood pressure. Clinical trials and scientific studies have shown high therapeutic efficacy of biologically active substances of plants, surpassing in some cases, medicines. So, the scent of lavender, chamomile, lemon, sandalwood is able to reduce the activity of the brain faster than the number of depressants. And Jasmine, rose, mint and cloves excite the cells of the gray matter is more powerful than therapeutic dose of caffeine (Soldatenko S. S., Nikolaev V. V. Essential oils. Ancient remedy. - http://Linkz.Ru. - 2004). It should be noted that the formulation of herbs is made empirically, based on the preferences and experience of the doctor. Virtually no standardized phyto-compositions.
A unified approach to the treatment of asthenic syndrome in TE according to the literature the authors found. Aromatherapy is used unreasonably rare, the selection of herbs is made empirically, there are no standardized phyto-compositions. Analogs of the invention can serve as a "Antisept" company "Armaform" (oil Caapucu, niaouli, ravensara, tea tree, eucalyptus); "Inhaler" cor�Orazio "Arterium" (eucalyptus oil, mint, fir, turpentine).
The technical result of the proposed method is to create the best mix of oils of eucalyptus, pine, cedarwood, peppermint, lavender and clove, with a maximum efficiency of treatment of asthenic syndrome in DAE by holding patients with asthenic syndrome in TEH essential oil inhalation by photocomposite "Biosecurity" containing 100 ml of eucalyptus oil 3.5 g, pine - 2.5 g, cedar - 2.5 g, mint - 3.5 g, lavender - 2.5 grams cloves - 0.5 g, base of linseed oil to 100 ml. the Course of treatment contains ten treatments. The first has a duration of 5 min (3 drops of aromatose), 2 and 3 treatments in 6 min (4 drops), 4 and 5 of the procedure for 7 minutes (5 drops), 6, and 7 procedures for 8 min (5 drops), 8 and 9 procedures 9 minutes (5 drops), 10 procedure - 10 minutes (5 drops).
A study of the effectiveness of aromatherapy in 78 patients with asthenic syndrome in DAE (mean age 45,4+11,2 years), the control group consisted of 38 patients of similar age who received standard therapy.
The proposed composition is prepared as follows: in a volumetric capacity alternately poured eucalyptus oil 3.5 g, pine - 2.5 g, cedar - 2.5 g, mint - 3.5 g, lavender - 2.5 grams cloves - 0.5 g. the Mixture is brought to a volume of 100 ml linseed oil. The mixing is performed by stirring. Inhalation was conducted in a physiotherapy�ucebnici OBUZ "City polyclinic №5", Ivanovo daily for 15 minutes in the Sauna apparatus inhaler TAKIO YH 1502. Complete apparatus consists of a steam inhaler, nozzles for inhalation and spray.
As criteria of effectiveness used the dynamics of clinical indicators, neuropsychological tests (short-term memory tests "Memory", "Memory of images", emphasis on "tables Schulte"), emotional status (test "Spielberg-Hanina", multifactor questionnaire RESINS), the dynamics of quality of life test "Health Status Survey (SF-36"). The study of cerebral blood flow according to rheoencephalography and bioelectrical brain activity using electroencephalography was performed on neurophysiological complex "Neuron-spectrum" (Ivanovo).
Statistical processing of results was carried out using parametric and nonparametric statistics on personal computer with using the program "Statistica 6.0" with the definition of mean values (M) average error (m), the criterion of reliability of student-Fisher (t), significance level (p), the criterion of homogeneity χ2. Differences were considered significant at p<0.05 or χ2>3,8.
In the study of clinical symptoms on the background of aromatherapy in the treatment group was observed the most marked improvement: intensity� headache decreased from 64.4 per cent (p< 0,05) patients, the noise in my head - in 24.5% (p<0,05), dizziness, sleep disturbances, memory loss and attention 31.1; 46,7 and 44.5%, respectively (p<0,05 in all cases). In the control group also demonstrated a positive trend, but it was significantly lower than in the main group.
After a course of aromatherapy average time spent on search numbers on the test Schulte, decreased in the main group of 24.2% (p<0,05). In the control group also demonstrated a positive trend, but it was significantly lower than in the main group.
After the treatment was observed an increase in the speed characteristics of blood flow by 10% in the first group. The positive effect of therapy was displaying in the trend to normalization of the main EEG rhythms. In patients on background treatment were registered, increasing the total spectrum of alpha-activity (mostly in the frontal and temporal areas), beta-1 activity (mainly in the Central region) and beta-2-activity (mostly in the temporal and Central regions). The average value of the total spectrum of theta and Delta activity decreased during treatment. The largest growth was recorded in the temporal, parietal and frontal lobes.
Example 1. Patient N. 45. Suffered from hypertension for 10 years. During the year notes irritability loss of sleep, confusion, reduced alertness, headache, sensation of noise in the head. In the neurological status is found expressed mild symptoms of oral automatism, asymmetry and abdominal tendon reflexes, mild incoordination. Background recording of the EEG is characterized by a decrease in the amplitude of the alpha rhythm (54 mV) and its disorganization. The oscillation frequency is 8.5 Hz. Beta rhythm has no clear topical characteristics. Periodically recorded slow wave Delta-, theta-band amplitude up to 30 mV in parietal derivations of the right hemisphere. According to REG showed signs of amiodarone, reduction of pulse blood filling, easy venous Disgaea. On the basis of complaints, anamnesis and neurological symptoms in a patient diagnosed with stage I-DAE, characterized by asthenia mainly with hypersthenic manifestations. A course of aromatherapy in the form of a daily inhalation of the essential oil composition "Biosecurity" scheme of treatment, consisting of ten treatments. The first has a duration of 5 min (3 drops of aromatose), 2 and 3 treatments in 6 min (4 drops), 4 and 5 of the procedure for 7 minutes (5 drops), 6, and 7 procedures for 8 min (5 drops), 8 and 9 procedures 9 minutes (5 drops), 10 procedure - 10 minutes (5 drops) on the unit Sauna inhaler TAKIO YH 1502. As a result of treatment marked improvement from the tummy.�I, associated with a heart rate and a decrease in the intensity of headaches and improved sleep.
|Dynamics of indicators of neuropsychological tests in patients with DAE in the studied groups before and after treatment (M±M)|
|Tests||Patients with TE|
|Main group (n=78)||The control group (n=38)|
|The average number of stored images on the test "Memory images"|
|The average number of memorized numbers on the test "Memory for numbers"|
Essential-oil composition for the treatment of asthenic syndrome in patients with discirculatory encephalopathy that contains oils of eucalyptus, peppermint, pine, cedar, Laban�s,
carnations, flax in the following ratio of components:
|eucalyptus oil||3.5 g|
|peppermint oil||3.5 g|
|oil of pine||2.5 g|
|the cedar oil||2.5 g|
|lavender oil||2.5 g|
|clove oil||0.5 g|
|oil flax||to 100 ml|
FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to ethinyl derivatives of formula I, where X represents N or C-R1; Y represents N or C-R2; Z represents CH or N; R4 represents 6-membered ring, containing 0, 1 or 2 nitrogen atoms, possibly substituted with 1-2 groups, selected from halogen, lower alkyl, lower alkoxy or NRR'; R1 represents hydrogen, lower alkyl, lower hydroxyalkyl, lower cycloalkyl or represents 5-6-membered heterocycloalkyl, containing 1-2 heteroatoms, selected from O and N; R2 represents hydrogen, CN; R and R' independently on each other represent hydrogen; or their pharmaceutically acceptable salts or acid-addition salts. Invention also relates to pharmaceutical composition, possessing activity of positive allosteric modulator of mGluR5 receptor, including effective quantity of at least one invention compound, and to application of invention compounds for manufacturing medication for treatment or prevention of diseases, associated with positive allosteric modulators of mGluR5 receptor.
EFFECT: obtained are novel compounds, which can be applied as positive allosteric modulator of mGluR5 receptor.
14 cl, 51 ex
SUBSTANCE: invention relates to pharmaceutical composition, possessing GABA-ergic activity, which contains 4[(4'-nicotinoylamino)butyroylamino]butanic acid, nicotinoyl gamma-aminobutyric acid, calcium salt of homopantothenic acid, thiamine chloride (vitamin B1), riboflavin (vitamin B2), pyridoxine (vitamin B6), nicotinic acid (vitamin B3), nicotinamide (vitamin B3*) calcium pantothenate (B5), folic acid (vitamin B9), cyancobalamine (vitamin B12) and as additional substances talc, calcium stearate, magnesium stearate, starch-sugar granulate, or microcrystalline cellulose, or lactose, where vitamin B1 is present in form of double granulate with polyvinylpyrrolidone and starch-sugar paste.
EFFECT: composition improvement.
5 cl, 3 tbl, 10 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to a storage-stable pharmaceutical composition and a pharmaceutical formulation containing at least one active pharmaceutical ingredient presenting a nitrocatechol derivative, 2,5-dichlor-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide, at least one excipients and at least one binding agent, wherein at least one excipient is other than a phosphate derivative, wherein at least one binding ingredient is other than a polyvinylpyrrolidone compound, and wherein the above active pharmaceutical ingredient is present in the granulated form.
EFFECT: compositions and/or formulations according to the invention are stable for a long period of time and show a high stability if stored in the high temperature and moisture environment.
26 cl, 8 tbl, 4 ex
SUBSTANCE: invention relates to synthetic biologically active substances of the heterocyclic series, having anticholinesterase activity, and is a product of modification of pyrodoxine acetals, specifically 1,5-dihydro-3-R1-3-R2-7,8-dimethyl-9-dimethylcarbamoyloxy-[1,3]dioxepino[5,6-c]pyridinium bromide of general formula I, where R1 is a hydrogen atom or a methyl, R2 is selected from: methyl, ethyl, propyl, iso-propyl, tert-butyl, heptyl, octyl or (1-methyldecyl). The compounds of formula (I) have high anticholinesterase activity and can be used in medicine and veterinary.
EFFECT: high activity of the compounds.
2 tbl, 11 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to a pharmaceutical composition, which contains formula compound as an active pharmaceutical ingredient or its pharmaceutically acceptable salt; and at least pharmaceutically acceptable filler, where the active pharmaceutical ingredient is present in an amount of at least 80% of the total dry weight of the composition.
EFFECT: composition possesses the good rate of release independently on the pH value.
8 cl, 4 dwg, 7 tbl, 4 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to biotechnology and represents anti-nerve growth factor (NGF) antibodies. The present invention also discloses a pharmaceutical composition for relieving pain associated with a disease or a condition, wherein pain progression or persistence is mediated by NGF, containing the above antibodies, as well as a kit for treating a HGF-related disease, such as e.g. osteoarthritis, nucleic acids coding a heavy or light chain of the antibody, an expression vector, a host cell for preparing the above antibodies, a method for expressing the above anti-NGF antibodies, as well as using the above antibodies in managing pain and for preparing a therapeutic agent for managing pain associated with the disease or condition, wherein pain progression or persistence is mediated by NGF.
EFFECT: present invention enables producing the anti-NGF antibodies characterised by high stability in vivo.
16 cl, 7 dwg, 13 tbl, 8 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: in general formula (I), X means CH2 or C=O; R means hydrogen, Ar1, Ar2-Ar3, -(CH2)qAr3, -C(O)Ar3, C(O) - (CRxRy)q-Ar3, -C(O) - (CRxRy)q-O-Ar3 or -C (O)-Ar2-AR3; each of the fragments Ar1, Ar2 and Ar3 means C6-10aryl or 5-13-merous heteroaryl containing 1, 2 or 3 heteroatoms specified in N, O or S; q means 1, 2 or 3; Rx and Ry independently mean hydrogen or alkyl; wherein each aryl or heteroaryl are independently unsubstituted or substituted by 1, 2 or 3 substitutes specified in a group of alkyl, halogen, cyano, -OR1a, -O-(CR4aR5a)p-O-, -C(O)R1a, -H(Rb)(R3a), -H(Ra)C(O)R1a and halogenalkyl; wherein R1a and R3a independently mean hydrogen or alkyl; and R4a and R5a mean hydrogen; Ra and Rb independently mean hydrogen or alkyl; p means 1 or 2.
EFFECT: invention refers to the compounds of formula (I) possessing an activity modulating α7 nicotinic acetylcholine receptors, α4β2 nicotinic acetylcholine receptors or both subtypes of α7 and α4β2 nicotinic acetylcholine receptors, the based pharmaceutical composition and methods of treating with using them.
18 cl, 1 tbl, 113 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a compound of formula , wherein Y and Z are independently specified in a group of a) or b) so that one of Y or Z is specified in the group a), and another one - in the group b); the group a) represents i) substituted C6-10aryl; ii) C3-8cycloalkyl; iii) trifluoromethyl or iv) heteroaryl specified in a group consisting of thienyl, furanyl, thiazolyl, isothiazolyl, oxazolyl, pyrrolyl, pyridinyl, isoxazolyl, imidazolyl, furasan-3-yl, benzothienyl, thieno[3,2-b]thiophen-2-yl, pyrazolyl, triazolyl, tetrazolyl and [1,2,3]thiadiazolyl; the group b) represents i) C6-10aryl; ii) heteroaryl specified in a group consisting of thiazolyl, pyridinyl, indolyl, pyrrolyl, benzoxazolyl, benzothiazolyl, benzothienyl, benzofuranyl, imidazo[1,2-a]pyridin-2-yl, furo[2,3-b]pyridinyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, thieno[2,3-b]pyridinyl, quinolinyl, quinazolinyl, thienyl and benzimidazolyl; iii) benzofused heterocyclyl attached through a carbon atom, and when a heterocyclyl component contains a nitrogen atom, the carbon atom is optionally substituted by one substitute specified in a group consisting of C3-7cycloalkylcarbonyl; C3-7cycloalkylsulphonyl; phenyl; phenylcarbonyl; pyrrolylcarbonyl; phenylsulphonyl; phenyl(C1-4)alkyl; C1-6alkylcarbonyl; C1-6alkylsulphonyl; pyrimidinyl and pyridinyl; C3-7cycloalkylcarbonyl, phenyl, phenylcarbonyl, phenyl(C1-4)alkyl and phenylsulphonyl are optionally substituted by trifluoromethyl, or by one or two fluor-substitutes; iv) phenoxatiynyl; vi) fluoren-9-on-2-yl; vii) 9,9-dimethyl-9H-fluorenyl; viii) 1-chlornaphtho[2,1-b]thiophen-2-yl; ix) xanthen-9-on-3-yl; x) 9-methyl-9H-carbazol-3-yl; xi) 6,7,8,9-tetrahydro-5H-carbazol-3-yl; xiii) 3-methyl-2-phenyl-4-oxochromen-8-yl; or xiv) 1,3-dihydrobenzimidazol-2-on-5-yl optionally substituted by 1-phenyl, 1-(2,2,2-trifluoroethyl), 1-(3,3,3-trifluoropropyl) or 1-(4,4-difluorocyclohexyl); 1-phenyl is optionally substituted by one or more fluor-substitutes or trifluoromethyl; or xv) 4-(3-chlorophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl; R1 represents C6-10aryl, C1-3alkyl, benzyloxymethyl, hydroxy(C1-3)alkyl, aminocarbonyl, carboxy, trifluoromethyl, spirofused cyclopropyl, 3-oxo or aryl(C1-3)alkyl; or when s is equal to 2 and R1 represents C1-3alkyl, the substitutes C1-3akyl is taken with a piperazine ring to form 3,8-diazabicyclo[3.2.1]octanyl or 2,5-diazabicyclo[2.2.2]octanyl ring system, and its pharmaceutical compositions.
EFFECT: preparing the new pharmaceutical compositions.
20 cl, 7 tbl, 72 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: general formula I involves both new, and known compounds. The compounds can be used for treating neuropathic pain mediated by Ih channel modulation and related inflammatory pain. In a compound of formula I. Ar means phenyl or a 6-merous heteroaryl group containing 1 or 2 nitrogen atoms, each of which can be optionally substituted by one or more substitute(s) specified in a group consisting of a halogen, (C1-4)alkyl, halogen(C1-4)alkyl, (C1-4)alkyloxy, halogen(C1-4)alkyloxy and (C1-4)alkylthio; X means O, S or NR1; R1 means H; R2 means (C1-4)alkyl, halogen(C1-4)alkyl or (C1-4)alkyloxy(C1-4)alkyl; R3 means H, (C1-4)alkyl, halogen(C1-4)alkyl or (C1-4)alkyloxy(C1-4)alkyl; Y1 means N; and Y2 and Y3 mean N or Y3 means CH, and Y2 independently means CH or N; R4 and R5 independently mean H, (C1-4)alkyl, halogen(C1-4)alkyl or (C1-4)alkyloxy(C1-4)alkyl; or R4 and R5 form a 3-7-merous saturated cycle together with a nitrogen atom which they are attached to.
EFFECT: invention refers to aminoheteroaryl derivatives having the general formula I, or their pharmaceutically acceptable salts.
12 cl, 11 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a pharmaceutical composition applicable for treating Down syndrome mediated by Dyrkla activity. The composition contains a compound of formula I in an effective amount and a pharmaceutically acceptable carrier. In Formula I, each R1 is independently specified in a group consisting of 3 and F; R2 represents S; R3 represents (CH2)m, wherein m is equal to 3; R4 represents H; R6 represents H; each R8 is independently -OR9 and each R9 independently represents 3 or C1-6alkyl.
EFFECT: invention refers to a method of treating Down syndrome mediated by Dyrkla activity.
7 cl, 1 dwg, 4 ex
SUBSTANCE: invention relates to medicine, namely to dentistry, therapeutic-prophylactic preparation for tooth and oral cavity care, and can be applied for prevention and complex treatment of inflammatory diseases of gums, parodentium, stomatitis or elimination of gingival hemorrhage. Therapeutic-prophylactic toothpaste includes glycerin, laurylglycoside, sorbitol, xylite, aerosol, calcium hydrogen phosphate, xanthane resin, sodium benzoate, CO2-extracts of thyme, sage, rosemary, white clay, green clay, red clay and water with specified content of components. For CO2-extracts of thyme, sage and rosemary fulfilled is ratio Wt/Ws/Wr=(0.40-0.50)/(0.25-0.35)/0.20-0.25), where Wt, Ws, Wr are weight parts of respectively CO2-extracts of thyme, sage and rosemary, with particles of green, white and red loam having sizes in interval 0.1-100 mcm and being obtained from clay, dried at 80-400°C.
EFFECT: technical result consists in increased efficiency of prevention and treatment of inflammatory diseases of oral cavity, parodentium, in particular gingivitis, periodontitis, as well as increase of cleaning ability of toothpaste with simultaneous reduction of abrasive influence on tooth enamel; and technical result consists in extension of arsenal or toothpastes of complex action, which render healing and preventive action on organs and tissues of oral cavity.
SUBSTANCE: invention relates to the poultry husbandry and can be used to stimulate the growth of poultry, increase in egg production. The proposed biologically active stimulant for poultry husbandry is an aqueous-alcoholic extract of the vegetative part of plants - Acanthopanax sessiliflorum and Patrinia scabiosifolia, taken in equal amounts.
EFFECT: invention enables to increase the weight gain of chickens, egg production of poultry, the preservation of birds, rate of fertilisation and hatchability of eggs.
SUBSTANCE: group of inventions relates to medicine, namely to dentistry, and can be used for the treatment of conditions, related with the increased expression of MMP-13, selected from the group, consisting of loss of one or more teeth fixation, teeth loss, teeth mobility, formation of recesses, bone tissue loss and a combination of two and more of the said conditions. For this purpose the application of 4-acetamidophenyl 2-isopropyl-5-methylcyclohexylcarbonate in the production of a medication for the treatment of the said conditions is claimed. A composition for teeth care, containing an orally acceptable carrier and a therapeutically effective quantity of a MMP-13 inhibitor in the form of 4-acetamidophenyl 2-isopropyl-5-methylcyclohexylcarbonate is also claimed.
EFFECT: group of inventions provides the effective treatment of the said conditions die to effective MMP-13 suppression.
3 cl, 5 tbl, 5 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to oral care agents. What is presented is using an oral care composition in the form of a mouthwash containing a fluoride ion source and a ternary polymer system consisting of xanthane gum, carboxymethyl cellulose and copovidone for dental erosion and/or wear control. This composition is also effective in dental caries control.
EFFECT: using fluoride ions in a combination with the ternary polymer system provides the better protection of the dental surface against dental erosion as compared to using fluoride ion only.
7 cl, 4 dwg, 5 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the chemical-pharmaceutical industry and represents an agent for preventing or reducing pigmentation, containing a compound presented by the following formula (1) its stereoisomer and/or its pharmacologically acceptable salt, wherein: R1 represents a hydrogen atom or an alkyl group with a linear or branched chain having 1-4 carbon atoms; R2 represents a hydrogen atom or an unsubstituted aliphatic hydrocarbon group having 1-4 carbon atoms; R3 represents an unsubstituted aromatic group having 5-15 carbon atoms, substituted by an alkyl group having 1-6 carbon atoms, by an alkoxy group containing an alkyl chain having 1-6 carbon atoms, or by a phenyl group; R3 also represents an aromatic group having 5-15 carbon atoms; n is equal to 1 or 2, and m represents an integer falling within 0 to 3.
EFFECT: preparing the agent for preventing or reducing pigmentation.
10 cl, 10 ex, 6 tbl
SUBSTANCE: hair care product is made in the form of gel, shampoo, lotion. All embodiments comprise aqueous vegetable extracts, phosphonate complex containing potassium-sodium salts of oxyethylidenebisphosphonic acid or their mixture with trisodium salt hexahydrate of phosphonformic acid and a cosmetically acceptable base.
EFFECT: hair care product is recommended for use in medicinal and cosmetic purposes for all ages for prevention and treatment of dystrophic changes in hairy part of the head.
SUBSTANCE: cosmetic product contains an aqueous solution of trace elements in amounts close to the daily demand of the human body, succinic acid which provides a high level of energy production (ATP), and also a bioregulatory complex obtained from hair follicles of calves, which stimulates proliferation of dormant cells of hair follicles.
EFFECT: increased efficiency of cosmetic product for complete prevention of hair loss caused by a wider range of reasons, and for partial or complete restoration of hair.
SUBSTANCE: invention relates to application of dry extract of aronia melanocarpa as hypolipidemic agent. Claimed extract is obtained by double extraction with 95% ethanol, acidified with hydrochloric acid, at heating on water bath.
EFFECT: claimed invention ensures obtaining agent with expressed ability to reduce level of triacylglycerols, total cholesterol and cholesterol in atherogenic lipoproteins of low density in blood serum.
3 tbl, 3 ex
SUBSTANCE: drops possessing antiviral and immunomodulatory effects characterised by the fact that they represent a 95% ethanol infusion of wild strawberry leaves and fruit specified in: red raspberry fruit, mountain ash fruit, bilberry fruit, blood-red hawthorn fruit, cinnamon rose fruit; 15-25 mg of the substance in 1 ml of the infusion.
EFFECT: drops possess pronounced antiviral and immunomodulatory effects.
15 tbl, 5 ex
FIELD: food industry.
SUBSTANCE: invention relates to a polyphenol grape extract, a compound for oral administration, a food product, beverage, a taste additive, a nutraceutical product, a revitalising composition and therapeutic remedy including the said grape extract. According to the invention, the grape extract contains nearly 5-15 wt % of monomers, nearly 5-20 wt % of dimers, nearly 3-10 wt % of trimers, nearly 2-10 wt % of tetramers and nearly 2-10 wt % of pentamers.
EFFECT: grape extract reduces blood pressure with patients suffering from prehypertonic condition or metabolic syndrome.
27 cl, 4 dwg, 8 tbl, 7 ex
FIELD: medicine, oncology, amino acids.
SUBSTANCE: invention relates, in particular, to the development of an antitumor preparation based on natural substances. Invention relates to an amino acid preparation comprising at least one modified essential amino acid obtained by treatment of amino acid by ultraviolet radiation (UV) at wavelength 250-350 nm for 12-80 h at temperature 15-30oC or with ozone at temperature 15-25oC. The modified amino acid has no toxicity for health cells. Also, invention relates to a method for preparing such preparation. Invention provides the development of an antitumor preparation based on modified amino acids and expanded assortment of antitumor preparations being without cytotoxicity for normal cells.
EFFECT: valuable medicinal antitumor properties of preparation.
8 cl, 4 tbl, 2 dwg, 4 ex